Intellia Therapeutics Reports Positive Phase 3 Results for HAE Treatment, Plans 2027 U.S. Launch
Intellia Therapeutics announced second quarter 2026 financial results alongside positive Phase 3 clinical data for lonvo-z in hereditary angioedema (HAE), with FDA biologics license application acceptance anticipated in late 2026 and U.S. commercial launch planned for first half of 2027.
